Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Germany: Activation of bitter taste receptors opens lung pathways, making them potential targets for the treatment of chronic lung diseases...
Read Full NewsA leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.
(Refiles to remove extraneous word years from first paragraph)
The Moderna vaccine will likely be available in Europe long before the US.
Saline lavage, alone or combined with intrapleural enzyme therapy, confers no clinically meaningful advantage over intrapleural enzyme therapy alone in patients with pleural infection.
Many doctors facing racism from patients stay silent, doubting they’ll be heard. Experts share strategies for handling bias when institutions fall short.
In patients with HIV‑1 infection and virologic suppression, switching to an investigational regimen of doravirine plus islatravir shows efficacy and safety similar to standard ART regimens.
Peak anti-hepatitis B surface antibody levels predicted increased viral protection in HIV, a French study shows.
1.
An understudied type of breast cancer poses a lurking threat
2.
Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer
3.
Testosterone recovery linked to overall survival in high-risk prostate cancer
4.
Eight Doctors Killed in Brazil's Horrifying Plane Crash
5.
Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?
1.
Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology
2.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
3.
Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases
4.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
5.
Uncovering Breast Cancer: The Power of Early Stage Ultrasound
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
5.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge